Tehran University of Medical Sciences Health Technology Assessment in Action 2645-3835 4 3 2021 06 09 48 48 Afsaneh Noormandi Department of Pharmacotherapy, Atieh Hospital, Tehran, Iran. Mohammad Fathalipour Department of Pharmacology and Toxicology, Faculty of Pharmacy, Hormozgan University of Medical Sciences, Bandar Abbas, Iran. Reza Daryabeygi-Khotbehsara Institute for Physical Activity and Nutrition, Deakin University, Geelong, Australia Soheil Hassanipour Guilan University of Medical Sciences, Rasht, Iran 2021 01 24 2021 04 07 Context: COVID-19 has been declared a global pandemic by the World Health Organization (WHO), infecting millions worldwide. The use of interferon (INF) subtypes previously examined in the treatment of SARS and MERS is also being initiated in some clinical trials. Although different clinical trials were evaluated IFNs in the treatment of COVID-19, their efficacy and safety remain unknown. Objectives: This study aimed to systematically assess IFNs efficacy and safety in treating patients with COVID 19. Methods: The protocol has been registered in the PROSPERO International Prospective Register (CRD42020200643) on 24 July 2020. This protocol has been arranged according to the PRISMA-P (Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols) 2015 checklist. Conclusions: Owing to lack of approved medication for COVID-19 treatment as well as various mutations of this virus, evaluation of the efficacy and safety of medications by various studies may help in finding treatments with high effectiveness. Interferons are one of the medications that have been administered in COVID-19. Moreover, the best time of administration and dose of this medication was unknown. Although meta-analysis is a potent source for assessing the accuracy of subjects, heterogeneity of articles is a potent limitation of this work. https://htainaction.tums.ac.ir/index.php/hta/article/view/48 https://htainaction.tums.ac.ir/index.php/hta/article/download/48/34